New Study Shows Semaglutide Drugs Not Linked to Increased Risk of Suicidal Thoughts
A new study conducted by researchers from the United States has found that semaglutide, the active ingredient in popular diabetes and weight loss drugs Ozempic and Wegovy, is not associated with an increased risk of suicidal ideation compared to other weight loss medications. The study, which is the first comprehensive analysis of its kind, comes in response to regulatory scrutiny after anecdotal reports of suicidal thoughts among users.
To conduct the study, researchers analyzed electronic health records of over 240,000 U.S. patients who were prescribed semaglutide or another medication for weight loss between June 2021 and December 2022. The aim was to determine the relationship between suicidal ideation and drugs like Ozempic and Wegovy.
The findings of the study revealed that patients who were prescribed semaglutide for weight loss had a risk of first-time suicidal ideation of only 0.11%. In contrast, patients who took other weight loss drugs reported a higher risk of 0.43%. Additionally, patients with a history of suicidal thoughts who took semaglutide had a lower risk of recurring suicidal ideations at 7%, compared to those who took other drugs at 14%.
Furthermore, the study found that individuals who took drugs like Ozempic and Wegovy had a significantly lower risk of first-time or recurring suicidal thoughts, ranging from 49% to 73%, in comparison to their counterparts taking different medications for weight loss. However, the study does not claim that semaglutide can prevent suicidal ideation, but it does suggest that there is no additional risk associated with taking semaglutide compared to other medications for obesity or diabetes.
Regulatory authorities such as the European Medicines Agency and the U.S. Food and Drug Administration (FDA) have been closely reviewing data on the risk of suicidal thoughts in patients taking GLP-1 receptor agonists, including semaglutide. The results of this study could potentially provide valuable insights for these agencies as they continue their evaluations.
Despite the potential health benefits of semaglutide, its availability remains limited due to high costs and restricted access. A monthly supply of Wegovy, for example, costs approximately $1,300, and private insurers rarely cover the medications or impose strict restrictions on access. As a result, access to semaglutide drugs is largely limited to those who can afford it.
Overall, this study provides reassuring evidence that semaglutide drugs like Ozempic and Wegovy are not associated with an increased risk of suicidal ideation compared to other weight loss medications. While further research and evaluation by regulatory authorities are required, these findings offer hope for individuals seeking safe and effective weight loss treatments.
“Prone to fits of apathy. Devoted music geek. Troublemaker. Typical analyst. Alcohol practitioner. Food junkie. Passionate tv fan. Web expert.”